
US-based Biofactura, Inc., founded in 2004, specializes in commercial physical and biological R&D.
Founded in 2004 and based in Frederick, Maryland, BioFactura, Inc. specializes in commercial physical and biological research and development. The company's core mission is to advance biopharmaceutical innovation, focusing on the development of biosimilars and biodefense therapeutics. BioFactura offers a range of products and services, including the development of biosimilar drugs like Ustekinumab and biodefense solutions such as smallpox therapeutics. Their market focus spans both the healthcare sector and national defense.
Notable figures affiliated with BioFactura include Jeffrey N. Hausfeld and Rodeina Challand. The company has achieved significant milestones, such as securing a multi-million dollar contract for its smallpox biodefense therapeutic and publishing phase data on its Ustekinumab biosimilar. These accomplishments underscore BioFactura's impact on both public health and biodefense, positioning it as a key player in the biopharmaceutical industry.

Biofrontera
biofrontera.com
Emergent BioSolutions

JK BioPharma Solutions

Secura Bio
securabio.com

Fabrus
fabrus.net

BioAnalytics

Superior Biologics

BiotecEra
biotecera.com

Actinobac Biomed

Veloce BioPharma

Biofisica
biofisica.com

Biolex Therapeutics

BioAnalytix
bioanalytixinc.com

BioHealthonomics

MacroGenics
macrogenics.com
Companies similar to BioFactura include Biofrontera, Emergent BioSolutions, JK BioPharma Solutions and Secura Bio.
BioFactura was founded in 2003.
BioFactura's headquarters is located in Frederick, MD, US.
BioFactura's most recent funding round was for $1M (USD) in July 2020.
As of Jul 28, 2020, BioFactura has raised a total of $76.2M (USD).
BioFactura has 33 employees as of Feb 5, 2024.